Title
|
|
|
|
Type of chemotherapy has substantial effects on the immune system in ovarian cancer
| |
Author
|
|
|
|
| |
Abstract
|
|
|
|
Chemotherapy induces a variety of immunological changes. Studying these effects can reveal opportunities for successful combining chemotherapy and immunotherapy. Immuno-chemotherapeutic combinations in ovarian cancer are currently not generating the anticipated positive effects. To date, only scattered and inconsistent information is available about the immune-induced changes by chemotherapy in ovarian cancer. In this study, we compared six common chemotherapeutics used in ovarian cancer patients (carboplatin, paclitaxel, pegylated liposomal doxorubicin, gemcitabine, carboplatin-paclitaxel and carboplatin-gemcitabine) and studied their effects on the immune system in an ovarian cancer mouse model. Mice received a single chemotherapy or vehicle injection 21 days after tumor inoculation with ID8-fluc cells. One week after therapy administration, we collected peritoneal washings for flow cytometry, serum for cytokine analysis with cytometric bead array and tumor biopsies for immunohistochemistry. Carboplatin-paclitaxel showed the most favorable profile with a decrease in immunosuppressive cells in the peritoneal cavity and an increase of interferon-gamma in serum. In contrast, carboplatin-gemcitabine seemed to promote a hostile immune environment with an increase in regulatory T-cells in tumor tissue and an increase of macrophage-inflammatory-protein-1-beta in the serum. |
| |
Language
|
|
|
|
English
| |
Source (journal)
|
|
|
|
Translational oncology
| |
Publication
|
|
|
|
2021
| |
DOI
|
|
|
|
10.1016/J.TRANON.2021.101076
| |
Volume/pages
|
|
|
|
14
:6
(2021)
, 8 p.
| |
Article Reference
|
|
|
|
101076
| |
ISI
|
|
|
|
000646136000003
| |
Pubmed ID
|
|
|
|
33770618
| |
Medium
|
|
|
|
E-only publicatie
| |
Full text (Publisher's DOI)
|
|
|
|
| |
Full text (open access)
|
|
|
|
| |
|